1 / 28

Insulin Initiation and Intensification in the Type 2 Diabetic Patient

Insulin Initiation and Intensification in the Type 2 Diabetic Patient. Jorge De Jesus MD FACE . Disclosures.

gore
Télécharger la présentation

Insulin Initiation and Intensification in the Type 2 Diabetic Patient

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Insulin Initiation and Intensification in the Type 2 Diabetic Patient Jorge De Jesus MD FACE

  2. Disclosures • Dr Jorge De Jesús has received honorariums as speaker for the following pharmaceutical companies: Bristol Myers-Squibb; Merck; Eli-Lilly; Astra-Zeneca; Boehringer- Ingelheim; Janssen • Dr Jorge De Jesús has no conflicts of interests with any entity for the information included in this presentation Jorge De Jesús MD FACE

  3. What is -cell dysfunction? Major defect in individuals with type 2 diabetes Reduced ability of -cells to secrete insulin in response to hyperglycemia     DeFronzo RA, et al. Diabetes Care 1992; 15:318–354.

  4. Why insulin therapy in type 2 diabetes?

  5. Antihyperglycemic Monotherapy Maximum Therapeutic Effect on A1C, dependent upon starting A1C Baseline A1C 8.51 Acarbose Nateglinide 8.3-8.52 Sitagliptin Bromocriptine 7.73 7.8-12.54 Liraglutide 8.2-8.55 8.06 Exenatide 10.0-10.37 Pioglitazone 8.8-9.08 Repaglinide Glimepiride 7.79 Glipizide GITS 8.3-8.810 9.7-10.111 Metformin Insulin 0 -1.0 -1.5 -2.0 -0.5 Reduction in A1C Level (%) 1. Precose [PI]. West Haven, CT: Bayer; 2003; 2. Hanefeld M et al. Diabetes Care. 2000;23:202–207; 3. Sitagliptin PI, Merck & Co, Inc, Whitehouse Station, NJ, 2010;1-23; 4. Kerr et al. Ann Pharm. 2010;44:1777-1785; 5. Blonde et al. DiabObesMetab. 2009;11(S3):26-34; 6. Nelson P, et al. Diabetes TechnolTher. 2007;9:317–326; 7. Aronoff S, et al. Diabetes Care. 2000;23:1605–1611; 8. Lebovitz HE, et al. J ClinEndocrinolMetab. 2001;86:280–288; 9. Goldberg RB et al. Diabetes Care. 1996;19(8):849-856; 10. Simonson DC et al. Diabetes Care. 1997;20(4):597-606; 11. Garber AJ, et al. Am J Med. 1997;102:491–497.

  6. Insulin • Remains the most powerful tool we have to control blood glucose • Dosing potential and A1C reduction only limited by risk of hypoglycemia • Patients with type 2 diabetes are at lower risk for hypoglycemia than type 1 patients Nathan DM, et al. Diabetes Care. 2006;29:1963-1972.

  7. When To Start Insulin in T2DM • When combination oral/injectable agents become inadequate • Have poor AM or daytime glycemic control • Unacceptable side effects of oral/injectable agents • Patient wants more flexibility • Special circumstances (i.e. steroids, infection, pregnancy) • Patients with hepatic or renal disease

  8. Normal Insulin Secretion 75 Bolus or Meal Response Dawn Phenomenon Basal or Background 50 Plasma Insulin (U/mL) Decrease at Night 25 0 4:00 8:00 12:00 16:00 20:00 24:00 4:00 8:00 Time (hrs) Polonsky W. Diabetes Educ. 2007;33(suppl 3):241S–244S.

  9. Treat to Target StudyInsulin Glargine vs. NPH Insulin Added to Oral Therapy • 9 Insulin glargine NPH insulin • 8 Mean A1C(%) • 7 Target A1C (%) 60% reach target A1C < 7% • 6 • 0 • 4 • 8 • 12 • 16 • 20 • 24 Weeks Riddle MC, et al. Diabetes. 2002;51(suppl 2):A113.

  10. Treat to Target Study: Cumulative Incidence of Hypoglycemia (N=756) PG 72 mg/dL ( 4.0 mmol/L) NPH insulin Insulin glargine Insulin Glargine vs. NPH in Overweight Patients with T2DM Cumulative Hypoglycemic Events NPH, Neutral protamineHagedorn; PG, plasma glucose. Riddle MC, et al. Diabetes Care. 2003;26:3080-3086.

  11. Detemir + OAD NPH + OAD Risk of Hypoglycemia with Detemir p < 0.001 18 16 14 12 Hypoglycemic events per patient per year 10 8 p < 0.001 6 4 2 0 Overall Nocturnal* * Any episode between 11 pm and 6 am Please see full prescribing information. Insulin detemir [package insert]. Bagsvaerd, Denmark; Novo Nordisk; 2009. NPH insulin [package insert]. Bagsvaerd, Denmark; Novo Nordisk; 2009. Hermansen K et al. Diabetes Care. 2006;29:1269-1274.

  12. Insulin Detemir vs. NPH Weight Profile 3 Insulin detemir *p<0.05, insulin detemir vs NPH insulin NPH insulin 2.5 2 * * * * * * * * * * * * 1.5 1 Weight change (kg) 0.5 0 Studies in type 2 diabetes -0.5 -1 Hermansen Standl Vague De Leeuw Pieber Pieber Home Home Russell-Jones Hermansen Rašlová Haak

  13. Long-acting insulin analogs are superior to NPH insulin because they provide a fairly flat response for approximately 24 hours and pro-vide better reproducibility and consistency both between subjects and within subjects, with a corresponding reduction in the risk of hypoglycemia. • Rapid-acting insulin analogs are superior to Regular because they are more predictable.

  14. 24-Hour Insulin Secretion and Replacement Aspart Lispro Glulisine Regular 50 Insulin (µU/mL) 25 Total Daily Dose (TDD) ~50% Bolus Insulin ~50% Basal Insulin 0 Breakfast Lunch Dinner Detemir Glargine NPH Riddle MC et al. The American Journal of Medicine. 2005;118(5A):14S–20S. Tanaka M. et al. The Journal of International Medical Research. 2010;38:674–68.

  15. Example: Starting Multiple Daily Injections in 100-kg Person with Moderate Insulin Resistance • Starting dose = 0.5 x wt in kg • 0.5 x 100 kg = 50 units • Basal dose = 50% of starting dose at bedtime • 50% of 50 units = 25 units at bedtime • Total bolus dose = 50% of starting dose evenly distributed1/3 at each meal • 25 units ÷ by 3 meals = 8 units before meals (TID)

  16. Meal Insulin Rapid-Acting Analogs (Lispro, Aspart, Glulisine) vs Regular Timing of food absorbed Analog insulin 10 8 6 Insulin Activity 4 Regular Human Insulin 2 0 1 2 3 4 5 6 7 8 9 10 11 12 0 Hours Howey DC, et al. Diabetes. 1994;43:396–402.

  17. Barriers to insulin initiation Patients refusal Insulin costs Fear of Hypoglycemia Myths Medical Inertia Patient education is time consuming Sometimes we transmit our concerns to patients even with non-verbal communication

  18. Es mejorprenderunavelitaquemaldecir la oscuridad Gracias Agradecer al Dr Harry Jimemnez por la ayuda en algunos visuales de esta presentacion

More Related